T cells hold the power to transform the treatment of devastating human diseases

Tmunity Therapeutics is a private biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T cell immunotherapy to more patients with devastating diseases.


Integrating broad collaborations with the University of Pennsylvania (UPenn) and the University of Minnesota with the groundbreaking scientific, clinical and manufacturing expertise and demonstrated track record of its founders, Tmunity is developing personalized immunotherapies for cancer, infectious disease and autoimmune disease that are advancing rapidly toward the clinic. With headquarters in Philadelphia, Tmunity utilizes laboratories and production facilities at UPenn and its own dedicated cGMP manufacturing facility in Norristown, PA, to pursue process improvement and production scale-up in support of clinical development of T cell therapies.


September 08, 2020

Tmunity Announces New Senior Leadership Appointments

February 19, 2020

Tmunity to Present at Upcoming Investor Conferences

Please reload

Tmunity is the new center of gravity in translational T cell medicine, inventing the future of cell-based immunotherapy today.

Tmunity is developing a diversified portfolio of novel treatments that exhibit best-in-class control over T cell activation and direction in the body.

“Extraordinary advances have already been made with the development of the first generation of cell-based immunotherapies for cancer. We formed Tmunity, bringing together all the essential expertise, technology and scientific insight, to make the next great leap, to deliver the full promise of T cell medicine to patients.”

Carl H. June, MD

Legal  |  Privacy  |  Cookies

Tmunity Therapeutics Inc.
3020 Market Street, Suite 535
Philadelphia, PA 19104


+1 215 966 1600

© 2020 Tmunity Therapeutics. All rights reserved.